Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 4, 2020

In an Instant: The Changing Face of Psychiatry

Author(s)P Priyanka, MD

FaceTime, Skype, and other video chat functions are the new normal in the COVID-19 era, and allow this community psychiatrist serve the underserved.

Medical Director for California-based Community Psychiatry, Dr Priyanka shares her experience with telepsychiatry and discusses the transformation of telemedicine before, during, and (hopefully) after COVID-19. Community Psychiatry is an outpatient psychiatric care company with over 120 clinicians in over 40 locations across California.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Cultural Competency and Community Engagement in Psychiatric Practice

Cultural Competency and Community Engagement in Psychiatric Practice

ByNaomi Dambreville, PhD

August 21st 2026

digital vs print

Digital Amnesia and Why Print Should Be Prized

ByRonald W. Pies, MD

August 21st 2026

Why Cultural Context Matters in Psychiatric Assessment

Why Cultural Context Matters in Psychiatric Assessment

ByNaomi Dambreville, PhD

August 20th 2026

Asking About Identity: A Collaborative Approach to Patient Care

Asking About Identity: A Collaborative Approach to Patient Care

ByNaomi Dambreville, PhD

August 19th 2026

neuropsychiatry

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

August 19th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Migraine and Psychiatric Comorbidities

Skin and Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle, With Judson Brewer, MD, PhD

Exploitation of Individuals With Psychosis

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment